Innovation Pharma’s Brilacidin inhibited SARS-CoV-2 by 97 percent in a human lung cell line
On Jun. 17, 2020, Innovation Pharma reported receiving data from ongoing laboratory testing being conducted at a U.S….
Innovation Pharma collaborated with regional biocontainment lab on grant application to research Brilacidin as pan-Coronavirus therapeutic
On Jun. 11, 2020, Innovation Pharma announced the Company and researchers at a U.S. Regional Biocontainment Laboratory (RBL)…
Innovation Pharma receives data from public health research institute showing brilacidin inhibits SARS-CoV-2 (COVID-19) in human cell line
On May 26, 2020, Innovation Pharma reported receiving data from a leading public health research institute showing Brilacidin…
Innovation Pharma pursuing gold standard in battle gainst Covid-19
On May 21, 2020, Innovation Pharma announced that in vitro research independently conducted at a U.S. Regional Biocontainment…
Innovation Pharma’s Brilacidin reduced viral titer of SARS-CoV-2 by 75 percent after 1 hour of preincubation in an in vitro study
On May 19, 2020, Innovation Pharma announced that its anti-SARS-CoV-2 (COVID-19) drug candidate, Brilacidin, in an in vitro…
Innovation Pharma announced the next phase of Brilacidin Coronavirus testing begun
On May 5, 2020, Innovation Pharma reported it had executed a Material Transfer Agreement (MTA) with a leading…
Screening of 11,552 compounds identified Innovation Pharma’s Brilacidin as promising Potential inhibitors of novel Coronavirus COVID-19
On Apr. 20, 2020, Innovation Pharma reported that based on molecular screening of 11,552 compounds comprising already FDA-approved…
Innovation Pharma in discussions to advance Brilacidin into human trials against COVID-19
On Apr. 6, 2020, Innovation Pharma announced that it is engaged in discussions with health care provider networks…
Innovation Pharma received data supporting Brilacidinﾒs direct inhibition of SARS-CoV-2
On Apr. 1, 2020, Innovation Pharma it had received data supporting Brilacidinﾒs direct inhibition of SARS-CoV-2, the novel…
Innovation Pharmaceuticals Brilacidin tested as drug and vaccine at different institutions
On Mar. 17, 2020, Innovation Pharma announced details on the Material Transfer Agreement signed with a leading public…
Innovation Pharma announced testing procedures of Brilacidin against Coronavirus
On Mar. 12, 2020, Innovation Pharma announced research procedures that one of the 12 Regional Biocontainment Labs (RBLs)…
U.S. Regional Biocontainment Lab to begin testing of Brilacidin against Coronavirus (COVID-19)
On Mar. 10, 2020, Innovation Pharma announced that management was advised that testing of Brilacidin, the Company’s flagship…
Innovation Pharma Brilacidin received by US Regional Biocontainment Lab for testing against COVID-19
On Mar. 9, 2020, Innovation Pharmaceuticals announced it was notified by one of the 12 Regional Biocontainment Labs…
Innovation Pharma signs second MTA to explore Brilacidin as Coronavirus COVID-19 treatment
On Mar. 6, 2020, Innovation Pharma announced that a second MTA has been signed to ship Brilacidin to…
Innovation Pharma provided scientific rationale and clinical development perspectives for Brilacidin as potential Coronavirus treatment
On Mar. 2, 2020, Innovation Pharma provided the scientific rationale and clinical development perspectives for Brilacidin, the Company’s…
Innovation Pharma shipped Brilacidin to U.S. Regional Biocontainment Laboratory for research against Coronavirus COVID-19
On Feb. 27, 2020, Innovation Pharma announced the Company had signed a Material Transfer Agreement (MTA) with one…
Innovation Pharma submited Material Transfer Agreement to study defensin mimetic Brilacidin for Coronavirus
On Feb. 24, 2020, Innovation Pharmaannounced the Company submitted a Material Transfer Agreement (MTA) with a leading U.S.-based…
Innovation Pharma’s Brilacidin tested as drug and vaccine at different institutions
On Feb. 18, 2020, Innovation Pharma announced the Company was exploring its lead defensin mimetic drug candidate, Brilacidin,…